Belite Bio (BLTE) said Thursday that an independent data safety monitoring board has advised continuing the phase 3 Dragon trial of Tinlarebant for adolescent Stargardt disease without altering the study's structure.
The recommendation to continue followed an interim analysis after all 104 participants completed a year of treatment and is expected to finish by Q4 without an increase in sample size, the company said.
Belite Bio also said Tinlarebant has shown a consistent safety profile, with no significant adverse effects reported, and most participants experienced stable vision that improved from baseline.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。